December 6-8, 2015 • Dubai, United Arab Emirates

Rick Cnossen, Intel Global Director- Healthcare

Transforming Healthcare with IoT

© 2015 Cisco and/or its affiliates. All rights reserved. 2

Intel's Vision

This decade we will create and extend computing technology to connect and enrich the lives of every person on earth

2

© 2015 Cisco and/or its affiliates. All rights reserved. 3

What’s Driving IoT in Healthcare?

Pay for Outcome

Wellness Programs

Reduce Cost of Chronic Care Reduce Readmissions

Patient Incentives Clinical Trials

Objective

Evaluate consumer perceptions

of technology innovations and

various ways that it is expected

to impact daily life.

Methodology

Penn Schoen Berland conducted

a quantitative poll with over

12,000 interviews, spanning

8 countries in Q3, 2013.

Intel Global Innovation Survey

4

Intel Global Innovation Survey

5

Intel Global Innovation Survey

6

How It All Started?

7

Big data analytics

IOT

Parkinson’s Disease

8

OVER AGE 0F 60

1/100 60,000 NEW

1M/US

5M/WORLD

NO CURE, MEDICATION ONLY HELPS WITH

SYMPTOMS There is

NO TEST and no

PROGRESSION MARKER

PARKINSON’S DISEASE IS CAUSED BY THE DEATH OF DOPAMINE CELLS.

OF THESE CELLS ARE ALREADY LOST BY THE TIME MOTOR SYMPTOMS APPEAR.

60

80%

TO

HOW?

9

Please raise your hand, if you can articulate how you have felt in the last

12 months in comparison to the previous year.

11

You can't Manage

what you can't Measure

The Solution

Wear a watch Start an application

12

1 2

Use Cases

MANAGE THE DISEASE USING DATA

FREE DATA FOR 1000’S OF PATIENTS

ACCURATE REPORT SINCE LAST VISIT

MEASURE MEDICATION EFFECT

RESEARCHER

PHARMACEUTICAL

CLINICIAN

BIG DATA CLOUD ANALYTICS

INSIGHT / VALUE

13

THE APPLICATION

14

10

Medication reporting & reminders

Questions per cohort

Symptoms tracking

OTHER Gamification

Contribution score

Medication / Protocol

Adherence Metronome

Gait Sleep

Tremor

Activity Level

Controlled Tests

Services: Data collection & Patient engagement

OBJECTIVE MEASURES

PATIENT REPORTED

Medication Reminders

Medication / Symptoms tracking

Questions per trail

Activity Level

• Continuously describe the intensity of the patient’s activity throughout the day alongside the medication reporting.

• Motivates the patients to be more active (known to be important for PD patients)

• Personalized measure based on their average activity (avoid frustration)

• Based on intensity measurement from the accelerometer

• Filters out tremor 17

Tremor

• Tremor is detectable using signal processing techniques

• Algorithm is based on tremor frequencies of 3.5Hz-11Hz according to literature review

• Tremor episodes are detected based on the frequency, duration and intensity of the periodic movement

18

Night Time Movement Tracking

• Most PD patients suffer from some sleep disorder and some have PD symptoms during the night

• Provide patients with movement analysis during the night

• Report on Low ,Medium and High activity periods during the night will allow the patients to better plan their sleep and wake up times as well as their medications

19

Structured Tests

BIG-DATA Analytics

21

Wearable Cloud Analytics Framework

Cloud Infrastructure

Data Platform

Analytics Platform

Downstream Export

Analysis & Mining tools

22

• Self reported – Questions, Feedbacks, Medication reporting • Structured tests – Gait, Alternating hand movement • 24/7 analyzed data– Activity, Tremor, Sleep

Analytics

CLINICAL TRIALS

Create and Validate Algorithm & Measures

POPULATION STUDY

23

Generate insights Using Big data analytics

SERVICE LAYER

BATCH LAYER

STREAM ANALYICS LAYER

INGESTION LAYER

STORAGE LAYER

USER INTERFACE LAYER

Mosquitto

24

CLOUD COMPUTING SERVICES

Domain Specific General Purpose

Challenges To Address

NO OBJECTIVE MEASURE

3-6 MONTHS BETWEEN PHYSICIAN VISITS

CHANGES ARE SLOW AND HARD TO DETECT

AVERAGE TRIAL SIZE

< 100 PATIENTS

VERY SMALL number of patients contribute to research

COST OF TRIALS are in the scales of

$M

25

© 2015 Cisco and/or its affiliates. All rights reserved. 26

Intel Healthcare Wearable Video Link

© 2015 Cisco and/or its affiliates. All rights reserved. 27

Intel Across Healthcare: Learn More

www.intel.com/healthcare Rick.a.cnossen@intel.com

Policy and Standards

Mobile Healthcare Care Coordination Secure Cloud Devices and Imaging

Performance Big Data Aging

2

7

© 2015 Cisco and/or its affiliates. All rights reserved. 28

Notice and Disclaimers

Notice: This document contains information on products in the design phase of development. The information here is subject to change without notice. Do not finalize a design with this information. Contact your local Intel sales office or your distributor to obtain the latest specification before placing your product order.

INFORMATION IN THIS DOCUMENT IS PROVIDED IN CONNECTION WITH INTEL® PRODUCTS. EXCEPT AS PROVIDED IN INTEL'S TERMS AND CONDITIONS OF SALE FOR SUCH PRODUCTS, INTEL ASSUMES NO LIABILITY WHATSOEVER, AND INTEL DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY RELATING TO SALE AND/OR USE OF INTEL PRODUCTS, INCLUDING LIABILITY OR WARRANTIES RELATING TO FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, OR INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER INTELLECTUAL PROPERTY RIGHT. Intel products are not intended for use in medical, life saving, or life sustaining applications. Intel may make changes to specifications, product descriptions, and plans at any time, without notice.

All products, dates, and figures are preliminary for planning purposes and are subject to change without notice.

Designers must not rely on the absence or characteristics of any features or instructions marked "reserved" or "undefined.“ Intel reserves these for future definition and shall have no responsibility whatsoever for conflicts or incompatibilities arising from future changes to them.

Performance tests and ratings are measured using specific computer systems and/or components and reflect the approximate performance of Intel products as measured by those tests. Any difference in system hardware or software design or configuration may affect actual performance.

The Intel products discussed herein may contain design defects or errors known as errata which may cause the product to deviate from published specifications. Current characterized errata are available on request.

Knights Corner, Knights Ferry, Aubrey Isle and other code names featured are used internally within Intel to identify products that are in development and not yet publicly announced for release. Customers, licensees and other third parties are not authorized by Intel to use code names in advertising, promotion or marketing of any product or services and any such use of Intel's internal code names is at the sole risk of the user.

opies of documents which have an order number and are referenced in this document, or other Intel literature, may be obtained by calling 1-800-548-4725, or by visiting Intel's website at http://www.intel.com.

Intel®, Itanium®, Xeon®, Pentium®, and the Intel logo are trademarks or registered trademarks of Intel Corporation or its subsidiaries in the United States and other countries.

Copyright © 2011-14015, Intel Corporation. All rights reserved.

*Other names and brands may be claimed as the property of others.

2

8